Strengthening Regulatory Oversight: Stem Cell and Gene Therapies Under Central Licensing

The CDSCO’s involvement ensures that these therapies undergo rigorous clinical trials and adhere to international safety benchmarks before reaching patients. Furthermore, this centralized approach addresses ethical concerns surrounding the manipulation of genetic material and the use of stem cells, providing a clear legal pathway for innovators while protecting public health. It also facilitates better monitoring of adverse events and ensures that medical institutions and private players maintain transparency in their therapeutic procedures. For the healthcare sector, this policy intervention represents a shift toward 'precision regulation,' where the government balances the need for rapid innovation in biotechnology with the necessity of patient safety. As India positions itself as a global hub for medical tourism and advanced research, such regulatory clarity is essential to build trust among patients and stakeholders alike. UPSC Relevance: This development is highly relevant for GS Paper II (Regulatory Bodies) and GS Paper III (Biotechnology). Aspirants can cite this as a case study on how the government updates regulatory frameworks to keep pace with rapid advancements in science and technology, ensuring both public safety and ethical governance in the health sector.